Skip to main content
SpringerLink
Log in

Immunopathology of Specific Cancers in Males and Females and Immunotherapy of Prostate and Cervical Cancer

  • Chapter
  • First Online:
Cancer Immunology

  • 801 Accesses

Abstract

Cancer remains one of the most complex diseases affecting humans, and despite the impressive advances that have been made in molecular and cell biology, how cancer cells progress through carcinogenesis and acquire their metastatic ability is still widely debated. Prostate cancer emerges from multiple alterations that induce changes in expression patterns of genes and proteins that function in networks controlling critical molecular and cellular events. Based on the exponential aging of the population and the increasing life expectancy in industrialized Western countries, prostate cancer is becoming a disease of increasing significance. While the incidence of cervical cancer has declined significantly in the USA, ethnic disparities remain in terms of increased mortality and morbidity. Here, it is aimed to review the clinical experiences and results achieved with immunotherapy for treating prostate and cervical cancers, two of the most significant malignancies in human males and females, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Grizzi F, Di Ieva A, Russo C, Frezza EE, Cobos E, Muzzio PC, et al. Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model. 2006;3:37.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Enderling H, Hahnfeldt P, Hlatky L, Almog N. Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy. Cancer Res. 2012;72:2172–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Deisboeck TS, Wang Z, Macklin P, Cristini V. Multiscale cancer modeling. Ann Rev Biomed Eng. 2011;13:127–55.

    Article  CAS  Google Scholar 

  4. Chakrabarti A, Verbridge S, Stroock AD, Fischbach C, Varner JD. Multiscale models of breast cancer progression. Ann Biomed Eng. 2012;40:2488–500.

    Article  PubMed  Google Scholar 

  5. Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013;341:80–96.

    Article  CAS  PubMed  Google Scholar 

  6. Grizzi F, Chiriva-Internati M. Cancer: looking for simplicity and finding complexity. Cancer Cell Int. 2006;6:4.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wang E, Zou J, Zaman N, Beitel LK, Trifiro M, Paliouras M. Cancer systems biology in the genome sequencing era: part 2. Evolutionary dynamics of tumor clonal networks and drug resistance. Semin Cancer Biol. 2013;23:286–92.

    Article  CAS  PubMed  Google Scholar 

  8. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013;62:203–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.

    Article  PubMed  Google Scholar 

  10. Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1–11.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev. 2011;12:CD007234.

    Google Scholar 

  12. Moskovic DJ, Miles BJ, Lipshultz LI, Khera M. Emerging concepts in erectile preservation following radical prostatectomy: a guide for clinicians. Int J Impot Res. 2011;23:181–92.

    Article  CAS  PubMed  Google Scholar 

  13. Lawrentschuk N, Trottier G, Kuk C, Zlotta AR. Role of surgery in high-risk localized prostate cancer. Curr Oncol. 2010;17(Suppl 2):S25–32.

    PubMed  PubMed Central  Google Scholar 

  14. Miyake H, Fujisawa M. Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. Int J Urol. 2012;20:301–11.

    Article  PubMed  Google Scholar 

  15. Lumen N, Fonteyne V, De Meerleer G, De Visschere P, Ost P, Oosterlinck W, et al. Screening and early diagnosis of prostate cancer: an update. Acta Clin Belg. 2012;67:270–5.

    CAS  PubMed  Google Scholar 

  16. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US preventive services task force review. J Clin Oncol. 2012;30:2581–4.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Eylert MF, Persad R. Management of prostate cancer. Br J Hosp Med (Lond). 2012;73(2):95–9.

    Article  CAS  Google Scholar 

  18. Spahn M, Haeni K. Approach to prostate cancer in men older than 75 years: active or passive? Urologe A. 2012;51:1368–74.

    Article  CAS  PubMed  Google Scholar 

  19. Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012;29:871–83.

    Article  CAS  PubMed  Google Scholar 

  20. Albrand G, Mottet N, Ruffion A, Flechon A, Bensadoun RJ, Gigante M, et al. Prostate cancer in elderly subjects: how diagnosis should be made, why and how geriatric assessment should be implemented. Prog Urol. 2012;22(Suppl 2):S55–63.

    Article  PubMed  Google Scholar 

  21. Lee CH, Akin-Olugbade O, Kirschenbaum A. Overview of prostate anatomy, histology, and pathology. Endocrinol Metab Clin N Am. 2011;40:565–75.

    Article  CAS  Google Scholar 

  22. Orsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2012;10:49–54.

    Article  PubMed  CAS  Google Scholar 

  23. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med. 2009;133:1033–40.

    CAS  PubMed  Google Scholar 

  24. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Aschelter AM, Giacinti S, Caporello P, Marchetti P. Genomic and epigenomic alterations in prostate cancer. Front Endocrinol (Lausanne). 2012;3:128.

    Article  CAS  Google Scholar 

  26. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 2009;69:7793–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.

    Article  CAS  PubMed  Google Scholar 

  28. Nakagawa H, Akamatsu S, Takata R, Takahashi A, Kubo M, Nakamura Y. Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. Cancer Sci. 2012;103:607–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA. Molecular pathology of prostate cancer. Cancer Biomark. 2010;9:441–59.

    Article  CAS  PubMed  Google Scholar 

  30. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72:1248–61.

    Article  PubMed  CAS  Google Scholar 

  31. Richiardi L, Fiano V, Grasso C, Zugna D, Delsedime L, Gillio-Tos A, et al. Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One. 2013;8:e68162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Barbieri CE, Demichelis F, Rubin MA. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology. 2012;60:187–98.

    Article  PubMed  Google Scholar 

  34. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM. Staging of prostate cancer. Histopathology. 2012;60:87–117.

    Article  PubMed  Google Scholar 

  35. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sun J, Turner A, Xu J, Gronberg H, Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol. 2007;25:250–9.

    Article  CAS  PubMed  Google Scholar 

  37. Foye A, Febbo PG. Cancer gene profiling in prostate cancer. Methods Mol Biol. 2010;576:293–326.

    Article  CAS  PubMed  Google Scholar 

  38. Golias C, Charalabopoulos A, Stagikas D, Giannakopoulos X, Peschos D, Batistatou A, et al. Molecular profiling and genomic microarrays in prostate cancer. Exp Oncol. 2007;29:82–4.

    CAS  PubMed  Google Scholar 

  39. Konishi N, Shimada K, Ishida E, Nakamura M. Molecular pathology of prostate cancer. Pathol Int. 2005;55:531–9.

    Article  CAS  PubMed  Google Scholar 

  40. Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett. 2008;271:13–24.

    Article  CAS  PubMed  Google Scholar 

  41. Yates C. Prostate tumor cell plasticity: a consequence of the microenvironment. Adv Exp Med Biol. 2011;720:81–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Franco OE, Hayward SW. Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. Adv Pharmacol. 2012;65:267–313.

    Article  CAS  PubMed  Google Scholar 

  43. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 2012;19:R187–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Iacopino F, Angelucci C, Sica G. Interactions between normal human fibroblasts and human prostate cancer cells in a co-culture system. Anticancer Res. 2012;32:1579–88.

    PubMed  Google Scholar 

  45. Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118:485–96.

    Article  CAS  PubMed  Google Scholar 

  46. Goldstein AS, Witte ON. Does the microenvironment influence the cell types of origin for prostate cancer? Genes Dev. 2013;27:1539–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One. 2012;7:e49278.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Singer E, Linehan J, Babilonia G, Imam SA, Smith D, Loera S, et al. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia. PLoS One. 2013;8:e60562.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Jia Z, Rahmatpanah FB, Chen X, Lernhardt W, Wang Y, Xia XQ, et al. Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS One. 2012;7:e41371.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, et al. Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res. 2011;71:2476–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Reinertsen T, Halgunset J, Viset T, Flatberg A, Haugsmoen LL, Skogseth H. Gene expressional changes in prostate fibroblasts from cancerous tissue. APMIS. 2012;120:558–71.

    Article  CAS  PubMed  Google Scholar 

  52. Vykhovanets EV, Maclennan GT, Vykhovanets OV, Gupta S. IL-17 expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Int J Clin Exp Pathol. 2011;4:552–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, et al. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013;73:5633–46.

    Article  CAS  PubMed  Google Scholar 

  54. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000;55:892–8.

    Article  CAS  PubMed  Google Scholar 

  55. Pittoni P, Colombo MP. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res. 2012;72:831–5.

    Article  CAS  PubMed  Google Scholar 

  56. Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, et al. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (−) NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer Immunol Immunother. 2010;59:1757–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kryvenko ON, Jankowski M, Chitale DA, Tang D, Rundle A, Trudeau S, et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol. 2012;25:1023–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60:199–215.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Flammiger A, Bayer F, Cirugeda-Kuhnert A, Huland H, Tennstedt P, Simon R, et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012;120:901–8.

    Article  CAS  PubMed  Google Scholar 

  60. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA. Leukocytic promotion of prostate cellular proliferation. Prostate. 2010;70:377–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Liu Y, Saeter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, et al. Dendritic and lymphocytic cell infiltration in prostate carcinoma. Histol Histopathol. 2013;28:1621–8.

    CAS  PubMed  Google Scholar 

  62. Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S. Immune system: a double-edged sword in cancer. Inflam Res. 2013;62:823–34.

    Article  CAS  Google Scholar 

  63. Snyder A, Tepper JE, Slovin SF. Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future? Semin Oncol. 2013;40:347–60.

    Article  CAS  PubMed  Google Scholar 

  64. Michael A, Relph K, Annels N, Pandha H. Prostate cancer vaccines. Exp Rev Vacc. 2013;12:253–62.

    Article  CAS  Google Scholar 

  65. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy. 2011;31:813–28.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Cheema Z, Hari-Gupta Y, Kita GX, Farrar D, Seddon I, Corr J, et al. Expression of the cancer-testis antigen BORIS correlates with prostate cancer. Prostate. 2013;74(2):164–76.

    Article  PubMed  CAS  Google Scholar 

  67. Chiriva-Internati M, Yu Y, Mirandola L, D’Cunha N, Hardwicke F, Cannon MJ, et al. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012;72:12–23.

    Article  CAS  PubMed  Google Scholar 

  68. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615–25.

    Article  CAS  PubMed  Google Scholar 

  69. Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic D, Heberer M, et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate. 2006;66(1):13–8.

    Article  CAS  PubMed  Google Scholar 

  70. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 2011;71:6785–95.

    Article  CAS  PubMed  Google Scholar 

  71. Ardiani A, Farsaci B, Rogers CJ, Protter AA, Guo Z, King TH, et al. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res. 2013;19:6205–18.

    Article  CAS  PubMed  Google Scholar 

  72. Kong HY, Byun J. Emerging roles of human prostatic acid phosphatase. Biomol Therapeut. 2013;21:10–20.

    Article  CAS  Google Scholar 

  73. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, et al. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother. 2013;62:1599–608.

    Article  CAS  PubMed  Google Scholar 

  76. Higano CS. Potential use of custirsen to treat prostate cancer. Onco Targets Ther. 2013;6:785–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005;26:129–42.

    CAS  PubMed  Google Scholar 

  78. Di Domenico F, De Marco F, Perluigi M. Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer. Exp Rev Proteomics. 2013;10(5):461–72.

    Article  CAS  Google Scholar 

  79. Okeke T, Onah N, Ikeako L, Ezenyeaku C. The frequency and pattern of female genital tract malignancies at the university of Nigeria teaching hospital, Enugu. Niger Ann Med Health Sci Res. 2013;3:345–8.

    Article  Google Scholar 

  80. Rossler L, Reich O, Horvat R, de Souza SC, Holl K, Joura EA. Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study. Wien Klin Wochenschr. 2013;125:591–9.

    Article  PubMed  CAS  Google Scholar 

  81. Deligeoroglou E, Giannouli A, Athanasopoulos N, Karountzos V, Vatopoulou A, Dimopoulos K, et al. HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol. 2013;2013:540850.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer. 2002;97:654–9.

    Article  CAS  PubMed  Google Scholar 

  83. Asiaf A, Ahmad ST, Mohammad SO, Zargar MA. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev. 2013;23:206–24.

    Article  CAS  Google Scholar 

  84. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo GA. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol. 2011;27:597–604.

    Article  PubMed  Google Scholar 

  85. Fernandes WC, Kimura M. Health related quality of life of women with cervical cancer. Rev Lat Am Enfermagem. 2010;18:360–7.

    Article  PubMed  Google Scholar 

  86. Amaro-Filho SM, Golub JE, Nuovo GJ, Cunha CB, Levi JE, Villa LL, et al. A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort. PLoS One. 2013;8(3):e57810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol. 2013;85(3):303–14.

    Article  PubMed  Google Scholar 

  88. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011;121(12):4593–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Jenkins M, Chiriva-Internati M, Mirandola L, Tonroy C, Tedjarati SS, Davis N, et al. Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol. 2012;31(1):3–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Chiriva-Internati M, Kast WM, Bot A. In this issue: targeting human papilloma virus-associated disease, from cervical to head and neck carcinoma…and more. Int Rev Immunol. 2012;31(1):1–2.

    Article  PubMed  Google Scholar 

  91. Powell N, Cuschieri K, Cubie H, Hibbitts S, Rosillon D, De Souza SC, et al. Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK). J Clin Virol. 2013;58(3):571–4.

    Article  PubMed  Google Scholar 

  92. Peralta-Zaragoza O, Bermudez-Morales VH, Perez-Plasencia C, Salazar-Leon J, Gomez-Ceron C, Madrid-Marina V. Targeted treatments for cervical cancer: a review. Onco Targets Ther. 2012;5:315–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol. 1994;75(Pt 8):2075–9.

    Article  PubMed  Google Scholar 

  94. Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol. 2004;35(8):971–82.

    Article  PubMed  Google Scholar 

  95. Morrow MP, Yan J, Sardesai NY. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines. 2013;12(3):271–83.

    Article  CAS  PubMed  Google Scholar 

  96. Liu Y, Chiriva-Internati M, Grizzi F, Salati E, Roman JJ, Lim S, et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 2001;8(12):948–57.

    Article  CAS  PubMed  Google Scholar 

  97. Chiriva-Internati M, Liu Y, Salati E, Zhou W, Wang Z, Grizzi F, et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol. 2002;32(1):30–8.

    Article  CAS  PubMed  Google Scholar 

  98. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, Guimaraes V, Rabot S, Alcocer-Gonzalez JM, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol. 2005;175(11):7297–302.

    Article  CAS  PubMed  Google Scholar 

  99. Zhou L, Zhu T, Ye X, Yang L, Wang B, Liang X, et al. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70. Hum Gene Ther. 2010;21(1):109–19.

    Article  CAS  PubMed  Google Scholar 

  100. Echchannaoui H, Bianchi M, Baud D, Bobst M, Stehle JC, Nardelli-Haefliger D. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun. 2008;76(5):1940–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Guirnalda PD, Paterson Y. Vaccination with immunotherapeutic Listeria monocytogenes induces IL-17(+) gammadelta T cells in a murine model for HPV associated cancer. Onco Targets Ther. 2012;1(6):822–8.

    Google Scholar 

  102. Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med. 2010;8:105.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Zhang H, Zhang J, Wang Z, Lu D, Feng J, Yang D, et al. CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer. Oncol Lett. 2013;5(4):1189–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Agarwal S, Saini S, Parashar D, Verma A, Jagadish N, Batra A, et al. Expression and humoral response of a-kinase anchor protein 4 in cervical cancer. Int J Gynecol Cancer. 2013;23:650–8.

    Article  PubMed  Google Scholar 

  105. Li FQ, Liu Q, Han YL, Wu B, Yin HL. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer. 2010;10:429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Hasegawa K, Koizumi F, Noguchi Y, Hongo A, Mizutani Y, Kodama J, et al. SSX expression in gynecological cancers and antibody response in patients. Cancer Immun. 2004;4:16.

    PubMed  Google Scholar 

  107. Riether C, Schurch C, Ochsenbein AF. From “magic bullets” to specific cancer immunotherapy. Swiss Med Week. 2013;143:w13734.

    Google Scholar 

  108. Mukherji D, Pezaro CJ, Shamseddine A, De Bono JS. New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat Rev. 2013;39:578–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study is partially supported by Rush Endowed Chair for Excellence in Women’s Health and Oncology and the Division of Hematology Oncology.

Author information

Authors and Affiliations

  1. Departments of Lymphoma & Myeloma, Gastroenterology, Hepatology& Nutrition, MDANDERSON Cancer Center, Kiromic BioPharma, The University of Texas, Houston, TX, USA

    Maurizio Chiriva-Internati

  2. Department of Immunology and Inflammation, Humanitas Research and Clinical Center, Milan, Rozzano, Italy

    Fabio Grizzi

  3. Kiromic LLC, Lubbock, TX, USA

    Leonardo Mirandola & Jose A. Figueroa

Authors
  1. Maurizio Chiriva-Internati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Grizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonardo Mirandola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jose A. Figueroa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurizio Chiriva-Internati .

Editor information

Editors and Affiliations

  1. Research Center for Immunodeficiencies Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chiriva-Internati, M., Grizzi, F., Mirandola, L., Figueroa, J.A. (2020). Immunopathology of Specific Cancers in Males and Females and Immunotherapy of Prostate and Cervical Cancer. In: Rezaei, N. (eds) Cancer Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-57949-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-57949-4_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-57948-7

  • Online ISBN: 978-3-030-57949-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation